Use of sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (HCC) appears to be effective, but the beneficial effect on survival is lost when the drug is used as a second-line or adjuvant therapy, a study has found.
Leuprolide acetate 22.5 mg, a novel 3-month depot formulation, is well tolerated and proves effective in achieving and maintaining testosterone concentration below castration levels in patients with prostate cancer, according to the results of a phase III trial.
Breast cancer patients experience consistent levels of anxiety and depression within the first year after surgery, a new study has found. Moreover, pessimism at baseline predicts changes in both anxiety and depression 5 years after diagnosis.
A family history of testicular cancer (TC), carcinoma, mesothelioma, sarcoma, malignant melanoma and malignant neuroepithelial tumours appears to increase the risk of paediatric and young adults’ TC, suggests a recent study.
Extended treatment with intermittent administration of letrozole among postmenopausal women with hormone receptor-positive breast cancer results in less symptom worsening during the first year compared with continuous endocrine therapy, results of the SOLE quality of life (QOL) sub-study have shown.
Decision making in men with newly diagnosed favourable-risk prostate cancer is driven by magnetic resonance imaging (MRI) and post-MRI biopsy, according to a study, noting that post-MRI biopsy is a stronger driver of decision making than MRI alone.
There appears to be a highly variable use of steroid for the management of immune-related adverse effect, according to a study, with most patients receiving prolonged courses of steroids and resuming checkpoint inhibitor therapy with concomitant steroids above recommended doses.
It appears that higher initial doses of romiplostim is safe for hospitalized patients with treatment-refractory immune thrombocytopaenia, reports a study. Higher initial doses, compared to dosing approved by the Food and Drug Administration, may shorten time to platelet responses and hospital length of stay.
Supplementation with folic acid and vitamin B12 potentially contributes to an increased risk of colorectal cancer, according to data from the B Vitamins for the Prevention of Osteoporotic Fractures (B-PROOF) trial.